Formulations and methods for treating rhinosinusitis

1. A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, said formulation comprising an aqueous suspension comprising:

a) 0.04% to 0.06% by weight of a suspended solid steroidal anti-inflammatory, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable salt, ester, enol ether, enol ester, acid, or base thereof, said suspended solid steroidal anti-inflammatory having the following particle size distribution profile:

i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.4 microns;

ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.8 microns;

iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;

iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and

v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 5.3 microns; wherein said formulation is suitable for administration to the nasal-paranasal mucosa;

b) from about 0.5 to 150 mg of an antifungal agent; and

c) at least at least one complexing agent selected from the group consisting of ethylenediaminetertraacetic acid, citric acid, nitrilotriacetic acid, salts thereof, and sodium edetate.

2. The formulation of claim 1 , wherein the steroidal anti-inflammatory is fluticasone propionate wherein;

greater than 90% or about 100% of the fluticasone propionate particles have a particle size of less than 10 microns.

3. The formulation of claim 1 , wherein the aqueous suspension is deliverable via an atomizing device.

4. The formulation of claim 3 , wherein the formulation is disposed in a metered dose spray pump.

5. The formulation of claim 1 , further comprising about 20 to about 70 mg of fluconazole or itraconazole.

6. The formulation of claim 5 , wherein the formulation comprises about 25 to about 50 mg of fluconazole or itraconazole.

7. The formulation of claim 6 , wherein the formulation comprises about 30 mg of fluconazole or itraconazole.

8. The formulation of claim 5 , wherein the formulation comprises about 7.5 to about 15 mg of amphotericin β.

9. The formulation of claim 1 , further comprising an antibiotic, antiviral agent, or combinations thereof.

10. The formulation of claim 9 , wherein the antibiotic is one or more of amikacin, azithromycin, aztreonan, cefazolin, cefepine, cefonicid, cefaperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, Cephapirin, ciprofloxacin, clindamycin, doxycycline, erythromycin lactobionate, gentamicin, kanamycin, linezolid, mezlocillin, mupirocin, nafcillin, netilmicin, neomycin, oxacillin, paromomycin, piperacillin, streptomycin, ticarcillin, tobramycin, or vancomycin.

11. The formulation of claim 1 , wherein the formulation is a sterile aqueous suspension.

12. The formulation of claim 1 , wherein the at least one complexing agent is sodium edetate.

13. The formulation of claim 1 , wherein said formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 90% of the mometasone originally present in the formulation still remains in the formulation.

14. The formulation of claim 1 , wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.

15. The formulation of claim 1 , further comprising neomycin sulfate.

16. A nasal spray formulation comprising:

an aqueous suspension having

a) 0.04% to 0.05% by weight of a suspended solid steroidal anti-inflammatory, wherein the suspended solid steroidal anti-inflammatory is beclomethasone or a pharmaceutically acceptable salt, ester, enol ether, enol ester, acid, or base thereof having the following particle size distribution profile:

i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.3 microns;

ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.6 microns;

iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.1 microns;

iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 1.8 microns; and

v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 2.7 microns; wherein said formulation is suitable for administration to the nasal-paranasal mucosa;

b) from about 0.5 to 150 mg of an antifungal agent; and

c) at least at least one complexing agent selected from the group consisting of ethylenediaminetertraacetic acid, citric acid, nitrilotriacetic acid, salts thereof, and sodium edetate.

17. The nasal spray formulation of claim 16 , wherein the formulation is disposed in a metered dose spray pump and further comprises about 10 to about 100 mg of doxycyline and a therapeutic amount of an antiviral agent selected from the group consisting of Acyclovir, Famciclovir, Valacyclovir, edoxudine, ganciclovir, foscarnet, cidofovir (vistide), Vitrasert and Formivirsen.

18. The nasal spray formulation according to claim 17 , wherein the formulation is disposed in a metered dose spray pump and further comprising ambient air as the propelling agent for delivering each spray of the metered-dose spray pump.

19. The nasal spray formulation of claim 16 , further comprising a preservative, suspending agent, wetting agent, buffer, diluent, or combinations thereof.

20. The nasal spray formulation of claim 16 , wherein the formulation further comprises one or more of the following compounds: (a) microcrystalline cellulose; (b) carboxymethyl cellulose sodium; (c) dextrose; (d) benzalkonium chloride; (e) polysarbate 80; or (f) phenylethyl alcohol.

21. The nasal spray formulation of claim 16 , wherein the antifungal agent is mphotericin β, fluconazole, itraconazole, or combinations thereof.

22. The nasal spray formulation of claim 16 , wherein said formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 90% of the beclomethasone originally present in the formulation still remains in the formulation.

23. The formulation of claim 16 , wherein the at least one complexing agent is sodium edetate.

24. The formulation of claim 16 , wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.

25. The formulation of claim 16 , further comprising neomycin sulfate.

26. A method of treating fungus-induced rhinosinusitis in a mammal, said method comprising the steps of applying to the mammal's nasal-paranasal mucosa a formulation according to claim 16 in each nostril of the mammal for 9 to 14 days.

27. The method of claim 26 , wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.

28. The method of claim 26 , formulation is applied via a metered-dose, manual pump spray unit.

29. A method of treating fungus-induced rhinosinusitis in a mammal, said method comprising the steps of applying to the mammal's nasal-paranasal mucosa a formulation according to claim 1 in each nostril of the mammal for 9 to 14 days.

30. The method of claim 29 , wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.

31. The method of claim 29 , formulation is applied via a metered-dose, manual pump spray unit.

32. The method of claim 31 , wherein the formulation is administered to the mammal as one spray in each nostril from 1 to about 10 times per day.

33. The method of claim 29 , wherein the formulation further comprises at least at least one complexing agent selected from the group consisting of ethylenediaminetertraacetic acid, citric acid, nitrilotriacetic acid, salts thereof, and sodium edetate.

34. The method of claim 33 , wherein the at least on complexing agent is sodium edetate.

35. The method of claim 29 , wherein said formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 90% of the beclomethasone originally present in the formulation still remains in the formulation.